Cue Biopharma Director Sarraf Pasha Receives 18,400 RSUs

What Happened
Sarraf Pasha, a director of Cue Biopharma, received a grant of 18,400 restricted stock units (RSUs) reported as an award (Code A) dated 2026-07-09. The RSUs were granted at $0.00 (no cash purchase); one-third of the shares vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to continued service. The Form 4 was amended on 2026-08-28 to correct an administrative error: the original filing overstated the grant as 21,800 RSUs.

Key Details

• Transaction date: 2026-07-09 (award/grant, Code A)
• Price: $0.00 per share (typical for RSU awards)
• Shares granted (corrected): 18,400 RSUs (originally reported as 21,800)
• Shares beneficially owned after grant: 29,195 (updated in the amendment)
• Vesting: One-third on 7/9/2027, 7/9/2028, 7/9/2029, subject to continued service
• Filing: Amended Form 4 filed 2026-08-28 to correct share count (administrative correction)

Context
RSU grants are compensation/retention awards and do not involve an open-market purchase or sale; they vest over time and typically do not signal immediate trading intent. This filing is an amendment correcting the number of RSUs originally reported — a bookkeeping correction rather than a change in the substance of the grant.